New drug combo aims to reawaken immune cells against tough cancers
NCT ID NCT05083481
First seen Sep 30, 2025 · Last updated Apr 29, 2026 · Updated 27 times
Summary
This study tests a new drug, ASP1570, in adults with advanced solid tumors that have not responded to standard treatments. The drug is given alone or with other cancer therapies to see if it can help the immune system fight the cancer. The main goals are to check safety and find the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China
-
California Research Institute
Los Angeles, California, 90027, United States
-
Cancer Institute Hospital Of JFCR
Koto-ku, Tokyo, Japan
-
ES34008
Málaga, Spain
-
FR33005
Saint-Herblain, France
-
FR33007
Besançon, France
-
FR33008
Paris, France
-
FR33009
Toulouse, France
-
Florida Cancer Specialist & Research Institute Sarasota
Sarasota, Florida, 34232, United States
-
Mary Crowley Research Center
Dallas, Texas, 75230, United States
-
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
-
Nebraska Methodist Hospital
Omaha, Nebraska, 68130, United States
-
Providence Medical Foundation
Fullerton, California, 92835, United States
-
Puerto Rico Medical Center
Río Piedras, Puerto Rico
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU)
Hangzhou, Zhejiang, China
-
Shanghai East Hospital
Shanghai, China
-
Site ES34002
Madrid, Spain
-
Site ES34005
A Coruña, Barcelona, Spain
-
Site ES34006
Pozuelo de Alarcón, Spain
-
Site ES34007
Málaga, Spain
-
Site FR33002
Bordeaux, France
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Kentucky Medical Center MCC-CRO
Lexington, Kentucky, 40536, United States
-
University of Wisconsin Clinical Science Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.